Amarin (NASDAQ:AMRN) Downgraded to “Strong Sell” Rating by Zacks Research

Zacks Research cut shares of Amarin (NASDAQ:AMRN) from a hold rating to a strong sell rating in a research report released on Tuesday morning,Zacks.com reports. Zacks Research also issued estimates for Amarin’s Q4 2025 earnings at ($2.93) EPS, FY2025 earnings at ($2.93) EPS, Q1 2026 earnings at ($2.71) EPS, Q2 2026 earnings at ($2.55) EPS, Q3 2026 earnings at ($4.22) EPS, Q4 2026 earnings at ($7.56) EPS, FY2026 earnings at ($17.05) EPS, Q1 2027 earnings at ($2.77) EPS, Q2 2027 earnings at ($2.77) EPS, Q3 2027 earnings at ($3.33) EPS, Q4 2027 earnings at ($6.46) EPS and FY2027 earnings at ($15.33) EPS.

A number of other equities research analysts have also weighed in on the company. Wall Street Zen lowered Amarin from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amarin in a research note on Wednesday, January 21st. Three research analysts have rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Strong Sell” and an average price target of $12.00.

Amarin Trading Down 2.0%

AMRN stock traded down $0.31 during trading on Tuesday, reaching $14.77. The stock had a trading volume of 10,235 shares, compared to its average volume of 95,924. The firm has a fifty day moving average price of $14.91 and a 200 day moving average price of $15.80. The company has a market capitalization of $306.96 million, a P/E ratio of -5.90 and a beta of 0.72. Amarin has a 1-year low of $7.08 and a 1-year high of $20.90.

Institutional Investors Weigh In On Amarin

Institutional investors have recently modified their holdings of the business. GPS Wealth Strategies Group LLC bought a new position in Amarin in the second quarter worth about $32,000. Banque Cantonale Vaudoise acquired a new position in Amarin during the 3rd quarter valued at approximately $32,000. Headlands Technologies LLC acquired a new position in Amarin during the 2nd quarter valued at approximately $44,000. Northwestern Mutual Wealth Management Co. grew its stake in Amarin by 1,816.7% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 5,750 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 5,450 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its stake in Amarin by 13.1% in the third quarter. Ameriprise Financial Inc. now owns 17,376 shares of the biopharmaceutical company’s stock valued at $285,000 after buying an additional 2,008 shares during the last quarter. Institutional investors own 22.25% of the company’s stock.

Amarin Company Profile

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies.

The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events.